Article Figures & Tables
Figures
- Figure 1:
Selection of double-blind placebo-controlled randomized controlled trials (RCTs) for inclusion in the systematic review and meta-analysis of the risk of serious adverse cardiovascular events associated with varenicline use. *An additional open-label trial of varenicline versus nicotine replacement therapy was included in the sensitivity analysis.
- Figure 2:
Meta-analysis of double-blind placebo-controlled randomized trials of the risk of serious adverse cardiovascular events associated with the use of varenicline. An odds ratio (OR) greater than 1.0 indicates an increased risk of a serious adverse cardiovascular event. CI = confidence interval.
Tables
- Table 1:
Characteristics of randomized controlled trials of varenicline included in the analysis of serious adverse cardiovascular events*
- Table 2:
Risk-of-bias assessment of randomized controlled trials (RCTs) of varenicline included in the analysis of serious adverse cardiovascular events*
- Table 3:
Sensitivity analyses for the outcome of serious adverse cardiovascular events*
In this issue
Article tools
Jump to section
Related Articles
Cited By...
- 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents
- Reprint of: Prevention and Treatment of Tobacco Use: JACC Health Promotion Series
- Prevention and Treatment of Tobacco Use: JACC Health Promotion Series
- Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital
- Interventions for smoking cessation in patients admitted with Acute Coronary Syndrome: a review
- Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease
- Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials
- Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
- Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome
- What are the effects of varenicline compared with nicotine replacement therapy on long-term smoking cessation and clinically important outcomes? Protocol for a prospective cohort study
- Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis
- Cardiovascular and neuropsychiatric safety of varenicline and bupropion compared with nicotine replacement therapy for smoking cessation: study protocol of a retrospective cohort study using the QResearch general practice database
- Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies: A Network Meta-Analysis
- The Effects of Nutritional Deficiencies, Smoking, and Systemic Disease on Orthopaedic Outcomes
- Does smoking cessation with varenicline worsen vascular endothelial function?
- Choice of summary statistics: relative and absolute measures
- Smoking Cessation After Acute Myocardial Infarction
- Bupropion for Smoking Cessation in Patients Hospitalized With Acute Myocardial Infarction: A Randomized, Placebo-Controlled Trial
- Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study
- Reducing the Cardiovascular Disease Burden: Justified Means for Getting to the End
- AAV-Directed Persistent Expression of a Gene Encoding Anti-Nicotine Antibody for Smoking Cessation
- Authors' reply to Singh and Loke
- Flaws in analysis lead to misleading conclusions about varenicline's safety in smoking cessation
- Varenicline for 4 weeks prior to target quit date reduces prequit date smoking and increases 12-week abstinence
- Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis
- Varenicline for smoking cessation: Is it a heartbreaker?
- Varenicline: quantifying the risk
- Varenicline: quantifying the risk
- Authors' response
- Authors' response
- Varenicline: quantifying the risk
- Varenicline: quantifying the risk
- Varenicline: quantifying the risk
- Varenicline: cardiovascular safety
More in this TOC Section
Similar Articles
Collections
